Last checked at 
TAIPEI, July 20 (Reuters) - Taiwan's Medigen Vaccine
Biologics Corp said on Tuesday it will start a
late-stage clinical trial this year in Paraguay for its COVID-19
vaccine, part of the island's push to make its own shots against
the coronavirus.
Taiwan's government on Monday approved the emergency use and
production of Medigen's vaccine despite criticism from
opposition parties the vaccine has yet to finish final clinical
trials and with no efficacy data available.
Health authorities in Paraguay have allowed Medigen to run
the Phase III trial involving 1,000 volunteers for the shot,
MVC-COV1901, the Taiwan-based company said in a filing to the
stock exchange.
Medigen said the trial is scheduled to complete in the third
quarter and data would be available in the fourth quarter,
adding the move will help expand the company's footprint in
Central and South America.
Paraguay is one of only 15 countries still to maintain
formal diplomatic ties with Chinese-claimed Taiwan.
Taiwan's health ministry has said there were no major safety
concerns during Phase II trials in Taiwan and studies so far
have shown that antibodies created were just as good as those
created by AstraZeneca's vaccine.
The government's decision to issue the EUA, however, has
sparked outcry from Taiwan's main opposition, the Kuomintang
(KMT).
On Tuesday it filed corruption charges against health
officials and called for the authorities to give more
information on how the EUA decision was made.
Health Minister Chen Shih-chung dismissed the move, saying
it would "only frustrate people who want to get on with things".
"I personally think this is not a good thing," he told
reporters.
Developing its own vaccine has been a major goal of Taiwan's
government, whose vaccination programme was delayed by global
supply shortages and had seen a rare uptick in domestic cases in
May, although the outbreak is now under control.
Medigen's shares closed up 10% on Tuesday after the EUA
announcement, compared with a 1.5 % fall in the broader market
.
(Reporting by Yimou Lee, editing by Louise Heavens)
